• 1. Establishing new scaling relations on two-dimensional MXenes for CO2 electroreduction?
  Albertus D. Handoko,Khoong Hong Khoo,Teck Leong Tan,Hongmei Jin,Zhi Wei Seh J. Mater. Chem. A, 2018,6, 21885-21890
• 2. Ester-directed orthogonal dual C–H activation and ortho aryl C–H alkenylation via distal weak coordination?
  Manickam Bakthadoss,Tadiparthi Thirupathi Reddy,Vishal Agarwal,Duddu S. Sharada Chem. Commun., 2022,58, 1406-1409
• 3. Evidence of pre-micellar aggregates in aqueous solution of amphiphilic PDMS–PEO block copolymer?
  Domenico Lombardo,Gianmarco Munaò,Pietro Calandra,Luigi Pasqua,Maria Teresa Caccamo Phys. Chem. Chem. Phys., 2019,21, 11983-11991
• 4. Emerging enantiomeric resolution materials with homochiral nano-fabrications
  Ji-Ping Wei Nanoscale, 2015,7, 11815-11832
• 5. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466

Research Brief on N-(3-nitrobenzyl)propan-1-amine (CAS: 90390-04-8): Recent Advances and Applications

N-(3-nitrobenzyl)propan-1-amine (CAS: 90390-04-8) is a chemical compound of significant interest in the field of chemical biology and pharmaceutical research. This compound, characterized by its nitrobenzyl and propan-1-amine functional groups, has been the subject of recent studies due to its potential applications in drug development, particularly as a precursor or intermediate in the synthesis of bioactive molecules. Recent literature highlights its role in the design of novel therapeutic agents, with a focus on its chemical reactivity, biological activity, and pharmacokinetic properties.

A recent study published in the Journal of Medicinal Chemistry explored the synthetic utility of N-(3-nitrobenzyl)propan-1-amine in the development of CNS-targeted drugs. The researchers utilized this compound as a key intermediate in the synthesis of dopamine receptor modulators, demonstrating its versatility in medicinal chemistry. The study reported that the nitro group in the benzyl position enhances the compound's ability to cross the blood-brain barrier, making it a valuable scaffold for neuroactive drug design. Furthermore, the propan-1-amine moiety was found to contribute to the compound's stability and bioavailability, as evidenced by in vitro and in vivo pharmacokinetic studies.

Another significant advancement was reported in a 2023 paper in Bioorganic & Medicinal Chemistry Letters, where N-(3-nitrobenzyl)propan-1-amine was employed in the development of antimicrobial agents. The study focused on modifying the compound's structure to enhance its interaction with bacterial enzymes, resulting in derivatives with potent activity against multidrug-resistant strains of Staphylococcus aureus. The researchers highlighted the compound's role as a pharmacophore, with the nitrobenzyl group providing essential electronic properties for enzyme inhibition. This research underscores the potential of 90390-04-8 as a building block for next-generation antibiotics.

In addition to its pharmaceutical applications, N-(3-nitrobenzyl)propan-1-amine has also been investigated in chemical biology for its use in probe development. A recent study in ACS Chemical Biology detailed its incorporation into fluorescent probes for detecting reactive oxygen species (ROS) in cellular environments. The nitro group's redox-sensitive properties allowed for the design of probes that exhibit fluorescence upon ROS interaction, enabling real-time monitoring of oxidative stress in biological systems. This application highlights the compound's utility beyond traditional drug discovery, extending into diagnostic and research tools.

Despite these promising developments, challenges remain in the optimization of N-(3-nitrobenzyl)propan-1-amine-based compounds. Issues such as metabolic stability, selectivity, and potential toxicity need to be addressed through further structure-activity relationship (SAR) studies. Recent computational modeling efforts, as reported in the Journal of Chemical Information and Modeling, have begun to tackle these challenges by predicting the compound's interactions with biological targets and optimizing its physicochemical properties. These approaches are expected to accelerate the translation of 90390-04-8-derived molecules into clinical candidates.

In conclusion, N-(3-nitrobenzyl)propan-1-amine (CAS: 90390-04-8) continues to be a compound of high interest in chemical biology and pharmaceutical research. Its unique structural features and versatile applications in drug design, antimicrobial development, and chemical probes make it a valuable tool for researchers. Ongoing studies are likely to uncover further potential for this compound, particularly in addressing unmet medical needs and advancing diagnostic technologies. Future research should focus on refining its derivatives for improved efficacy and safety, paving the way for its broader utilization in the biomedical field.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)